Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases

a technology antimicrobial treatment, which is applied in the field of human immunodeficiency virus, can solve the problems of non-infectious virus formation, rt inhibitors can interrupt this process, and viral structural proteins cannot be properly manufactured, so as to prevent the spread of hiv, prevent the attachment of human immune deficiency virus, and prevent the sexual transmission

a technology antimicrobial treatment, which is applied in the field of human immunodeficiency virus, can solve the problems of non-infectious virus formation, rt inhibitors can interrupt this process, and viral structural proteins cannot be properly manufactured, so as to prevent the spread of hiv, prevent the attachment of human immune deficiency virus, and prevent the sexual transmission

US20060024393A1Inactive Publication Date: 2006-02-02SQUIRES MERYL J
15 Cites 10 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
  • Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
  • Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases

Examples

Experimental program
Comparison scheme
Effect test

examples 1-7

In Vivo Testing

[0093] In an initial, topical application, in-vivo study that was undertaken to evaluate the effects of the medical treatment and medicine of the present invention upon seven human test subjects who had been tested positive for HSV 1 or 2. The subjects were treated topically with the medicine comprising benzalkonium chloride surfactant in an aqueous solution (at a ratio of 1:750) in combination with the herbaceous botanical Echinacea purpurea in powdered form containing the previously listed phytochemicals. Application of the composition was made by a two-step procedure by first wetting the affected area or vesicle with the benzalkonium chloride surfactant in an aqueous solution by spraying, dabbing, or using a dropper; then applying a coating of the powdered phytochemicals over the wetted area by either swab or manually sprinkling the powder onto the infected area. An important aspect in this treatment was maintaining complete coverage of the affected area for the d...

examples 8-13

Dermatological and Veterinary Testing

[0100] Animal testing to determine any possible dermatological allergic reaction induced by the medical composition (medicine) was undertaken. Six animal subjects were used. The animals included 3 female rabbits (ages unknown); 2 dogs (1 female 2 year old, and 1 male 9 year old); one, 3 year old neutered male cat. In these animal tests, the above composition (medicine) was applied, in the previously stated method, to the inside of the outer ear of each animal. In all instances, the area being treated was kept coated with the compound for twenty-four hours, matching the time human subjects had used. The testing performed on the six animal subjects indicated that there were no signs of dermatological irritation or allergic reaction.

example 14

[0101] The above medical compound containing viral inhibitors was also tested on a papilloma virus caused wart on the muzzle of a two year old gelded thoroughbred horse. Papilloma virus warts are difficult to treat. The wart measured 25 mm in diameter. The antimicrobial compound (medicine) was applied twice daily. The wart was then measured at each application.

[0102] Results: Quite unexpectedly, the wart decreased dramatically in size by approximately 3 mm per day while the medicine was applied to the wart and on the fifth day fell off completely. It was observed that, at first the surface layers of the wart began to degrade, exposing large erythematous papules. Then interestingly, the warts did not just diminish in size by flaking or peeling, they diminished at the point of attachment on the subject's epidermis and fell off still somewhat intact with no sequela scarring.

[0103] In an ongoing, long term in vivo study of this invention, which began with the first seven subjects in A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
median timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochemicals, benzalkonium chloride, a sterile water solution, and folic acid.

Description

CROSS REFERENCES TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 084,759 filed on Feb. 26, 2002 which in turn is a continuation of U.S. Ser. No. 08 / 824,041 filed on Mar. 26, 1997, now U.S. Pat. No. 6,350,784, which in turn is a continuation-in-part of U.S. Ser. No. 08 / 646,988 filed on May 8, 1996, now U.S. Pat. No. 6,355,684, which in turn is a continuation-in-part of U.S. Ser. No. 08 / 600,217, filed on Feb. 12, 1996, now U.S. Pat. No. 6,348,503.BACKGROUND OF THE INVENTION [0002] The present invention relates to human immunedeficiency virus, and more particularly, to medical treatments and preventions for human immunedeficiency virus and other microbial infections. [0003] It has been reported that there are currently about 22 million people infected with human immunedeficiency virus (HIV) throughout the world. The largest proportion of new HIV cases have originated in Africa and the Caribbean. The typical progression of HIV inf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
02 Feb 2006
Publication
US20060024393A1
IPC
A61K36/328; A61K36/28; A61K31/714; A61K45/08; A61K9/14; A61K31/045; A61K31/12; A61K31/14; A61K31/16; A61K31/195; A61K31/198; A61K31/216; A61K31/343; A61K31/7032; A61K36/18; A61K36/534; A61K36/537; A61K36/61; A61K36/68; A61K36/81; A61K36/8962; A61K38/27; A61K38/28; A61K45/06; A61P31/00; A61P31/04; A61P31/12; A61P31/18; C07D417/06
CPC
A61K9/145; A61K31/14; A61K31/195; A61K31/198; A61K31/714; A61K36/28; A61K36/328; C07D417/06
Inventors
SQUIRES, MERYL J.